Prognostic impact of primary versus secondary resistance to sorafenib in patients with HCC by Jin Lei, Hongyuan Dai, Ya Zhang, Guangling Ou, Zhi Peng Liang, Yinying Lu, Haiyang Li

“…Patients in the primary group had significantly shorter median OS than those in the secondary group (9.0 months vs 23.0 months, p  < 0.001). Compared with tyrosine kinase inhibitor (TKI) monotherapy, the use of TKI plus PD-1 inhibitor combination therapy as second-line treatment conferred a longer median PFS (6.0 vs 10.0 months, p  < 0.001) and OS (13.0 vs 22.0 months, p  < 0.001). …”
Get full text

Cytomegalovirus Infection in Patient with Clear Cell Renal Cell Carcinoma by Ikhwan Rinaldi, Abdul Muthalib, Januar Widodo Sutandar, Hendro Adi Kuncoro, Bambang Irawan Harsono, Nelly Susanto, Tjondro Setiawan, Kevin Winston, Idham Rafly Dewantara, Ihya Fakhrurizal Amin, Yuli Maulidiya Shufiyani

“…In this case report, we present the case of a 61-year-old man with clear cell renal cell carcinoma who underwent targeted therapy with the receptor tyrosine kinase (RTK) inhibitor lenvatinib and the mammalian target of rapamycin (mTOR) inhibitor everolimus. …”
Get full text

Sudden Vision Loss Secondary to Optic Nerve Infiltration as a Presenting Symptom of Metastatic Lung Adenocarcinoma by M. M. Shamim, M. Whaley, H. Rana, S. K. Jeffus, S. Bhatti, A. B. Sallam

“…Further investigation into the role of tyrosine kinase inhibitors and radiation therapy in treating intraocular metastasis involving the optic nerve is needed.…”
Get full text

Patient Preferences for Chronic Myeloid Leukemia Medication Regimen Attributes and their Potential Impact on Adherence: Results from a Multi-national Conjoint Study by Ishan Hirji, Jessica Grinspan, Emuella Flood, Diana Chirovsky, Jennifer Devlen, Samuel Wagner, Catherine Davis

“…**Background:** Tyrosine kinase inhibitors (TKIs) have significantly improved survival for patients with chronic myeloid leukemia (CML) but require long-term administration and non-adherence due to regimen requirements has been reported. …”
Get full text

Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy by Zhuomiao Lin, Meiqing Yang, Xihui Yu, Guozhu Tan, Jiahong Zhong

“…Ponatinib, a third-generation tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia, was found to improve metabolic disorders in mice. …”
Get full text

Features of diagnosis and treatment of gastrointestinal stromal tumors by N. I. Bogomolov, T. V. Burdinskaya, M. A. Goncharova, A. G. Goncharov, N. N. Tomskikh

“…Targeted therapy by tyrosine kinase inhibitors was carried out for 14 patients. …”
Get full text

Impact of Hemoglobin, Leucocyte and Thrombocyte Levels at Diagnosis on the Survival Outcomes of Chronic Myeloid Leukemia Patients by Taha Ulutan Kars, Atakan Tekinalp, Rafiye Ciftciler, Sinan Demircioğlu

“…Background:Since the development of tyrosine kinase inhibitors (TKIs), the prognosis for chronic myeloid leukemia (CML) has significantly improved. …”
Get full text

Isolated Central Nervous System Infiltrated and Progressed to Acute Myeloid Leukemia from Chronic Myeloid Leukemia with e1a3 BCR-ABL1 Transcript: A Rare Case Report and Literature... by Qiang X, Wen Q, Li J, Chen S, Tao T, Zhang H, Wang P, Peng X, Feng Y, Zhang X

“…Following initial diagnosis, the patient was treated with the tyrosine kinase inhibitor (TKI) Flumatinib. During the treatment, although the FCM-MRD of the bone marrow kept negative, the e1a3 expression detected by PCR always remained positive. …”
Get full text

Aggressive Papillary Thyroid Carcinoma Presenting with Metastasis to the Pancreas by Firas Warda, Sam Ho, Enoch Kuo, Dinesh Rao, Marilu Jurado-Flores

“…Surgical resection can be curative and can be followed by radioactive iodine ablation therapy if cancer cells show avidity. Tyrosine kinase inhibitors can be used in refractory disease. …”
Get full text

Promising horizons in achondroplasia along with the development of new drugs by Keiichi Ozono, Takuo Kubota, Toshimi Michigami

“…Additionally in development are a tyrosine kinase inhibitor, a soluble FGFR3, an antibody against FGFR3, meclizine, and the FGF2-aptamer. …”
Get full text

FGFR antagonists restore defective mandibular bone repair in a mouse model of osteochondrodysplasia by Anne Morice, Amélie de La Seiglière, Alexia Kany, Roman H. Khonsari, Morad Bensidhoum, Maria-Emilia Puig-Lombardi, Laurence Legeai Mallet

“…Lastly, we found that treatment with a tyrosine kinase inhibitor (BGJ398, infigratinib) or a C-type natriuretic peptide (BMN111, vosoritide) fully rescued the defective endochondral bone repair observed in Hch mice. …”
Get full text

Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention by Rodrigo Fonseca, Yuan Xiao Zhu, Laura A. Bruins, Joseph Ahmann, Cecilia de Bonolo Campos, Esteban Braggio, Xianfeng Chen, Mariano Arribas, Susie Darvish, Seth Welsh, Erin Meermeier, Kiran K. Mangalaparthi, Richard K. Kandasamy, Greg Ahmann, J. Erin Wiedmeier-Nutor, Akhilesh Pandey, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca

“…Upstream signaling pathways, including growth factor receptor tyrosine kinase (RTK) and phosphoinositide-3-kinase (PI3K) were implicated in this dysregulation. …”
Get full text

Antifibrotic Effect of Combination of Nilotinib and Stem Cell-Conditioned Media on CCl4-Induced Liver Fibrosis by Gamal Shiha, Ahmed Nabil, Ahmed Lotfy, Reham Soliman, Ayman A. Hassan, Islam S. Ali, Doaa F. Gad, Faten Zahran

“…Nilotinib is a second-generation tyrosine kinase inhibitor, which showed antifibrotic efficacy. …”
Get full text

A novel sensitizer reduces EGFR-TKI resistance by regulating the PI3K/Akt/mTOR pathway and autophagy by Jue Zhang, Zhipeng Qu, Xi Xiao, David L. Adelson, Funeng Wang, Aisheng Wei, Yuka Harata-Lee, Jian Cui, Dongying He, Le Xie, Lingling Sun, Jing Li, Zijing Huang, Thazin Aung, Hong Yao, Lizhu Lin

“…Background: The incidence and mortality of lung cancer are high, and treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the preferred first-line treatment for patients suffering from non-small cell lung cancer (NSCLC) with EGFR mutations. …”
Get full text

Altered Forebrain Functional Connectivity and Neurotransmission in a Kinase-Inactive Mouse Model of Autism by Shiyu Tang PhD, Elizabeth M. Powell PhD, Wenjun Zhu MS, Fu-Sun Lo MD, Reha S. Erzurumlu PhD, Su Xu PhD

“…MET , the gene encoding the tyrosine kinase receptor for hepatocyte growth factor, is a susceptibility gene for autism spectrum disorder (ASD). …”
Get full text

PRMT1 Promotes the Self‐renewal of Leukemia Stem Cells by Regulating Protein Synthesis by Min Zhou, Yi Huang, Ping Xu, Shuyi Li, Chen Duan, Xiaoying Lin, Shilai Bao, Waiyi Zou, Jingxuan Pan, Chang Liu, Yanli Jin

“…Abstract The application of tyrosine kinase inhibitors (TKIs) has revolutionized the management of chronic myeloid leukemia (CML). …”
Get full text

How Much Time Should Be Waited and What Are the Main Findings to Evaluate the Hepatocellular Carcinoma Response to Regorafenib? A Real-Life Experience by Gustavo Hideki Kawanami, Leopoldo Katsuda, Thiara Barcelos Rocha, Fabio da Silva Yamashiro, Leonardo Pelafsky, Xingshun Qi, Fernando Gomes Romeiro

“…In addition, some clinical and imaging findings can be deemed as predictors of good response to tyrosine kinase inhibitors.…”
Get full text

Case report: A panorama gene profile of ovarian cancer metastasized to axillary lymph node by Yu Xia, Yu Huang, Zheng Liu, Siyuan Song, Yi Wang, Yi Wang, Jing Luo

“…Further analysis of NGS identified two novel missense mutations, D326E in BTK (Bruton’s tyrosine kinase) at SH2 domain and D251E in EPHA5 (EPH receptor A5), along with other known cancer- associated mutations. …”
Get full text

The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases by Kazuhiro Usui, Tomonori Ushijima, Yoshiaki Tanaka, Chiharu Tanai, Hiromichi Noda, Norifumi Abe, Hajime Horiuchi, Teruo Ishihara

“…Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective in patients with nonsmall cell lung cancer with epidermal growth factor receptor (EGFR) mutation, EGFR-TKIs have a risk of inducing fatal interstitial lung disease (ILD). …”
Get full text

A novel imatinib analogue inhibitor of chronic myeloid leukaemia: design, synthesis and characterization—explanation of its folded conformation by Rodolfo Moreno-Fuquen, Juan F. Avellaneda-Tamayo, Kevin Arango-Daraviña, Javier Ellena, Alan R. Kennedy

“…Chronic myeloid leukaemia (CML) is primarily treated using imatinib mesylate, a tyrosine kinase inhibitor (TKI) targeting the BCR::ABL1 oncoprotein. …”
Get full text